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Patient 1. A 67-year-old man was admitted to the general medical
service at the Charitable Infirmary, Jervis Street Hospital (now Beau-
mont Hospital) with a right-sided stroke and somnolence. The blood
pressure was 180/112 mm Hg.
He had first sought medical attention 8 years previously, when severe
Raynaud's phenomenon, present for 3 years, became intolerable. He
did manual work, although he did not use vibrating tools or jackham-
mers. The skin over his fingertips was shiny, indurated, and puckered;
nailfold capillaroscopy was abnormal; and the blood pressure was
150/94 mm Hg. Alpha-methyldopa, 250 mg twice daily, was prescribed.
Relevant investigations at that time included a barium swallow,
which showed a dilated upper esophagus with lower esophageal sphinc-
ter laxity; a chest radiograph, which revealed changes of early tower-
lobe fibrosis; and plain radiographs of his hands, which disclosed early
resorption of the distal phalangeal tufts. The anti-nuclear antibody test
was weakly positive at a titer greater than 1:32 with a speckled pattern;
tests for anti-ribonucleoprotein and anti-centromere antibodies were
negative. The serum creatinine was 1.3 ing/dI; urinalysis showed a
specific gravity of 1.024; pH, 5.8; and 60 mg/dl of protein. The urinary
sediment contained 100 red blood cells/high-power field and occasional
granular casts. A 24-hour urine collection contained 1360 mg of creat-
mine and 490 mg of protein. Creatinine clearance was 74 mI/mm.
Early retirement from his job was arranged, and he was seen
regularly up to the time of the current admission. His clinical course
was typical for diffuse cutaneous scleroderma; various changes in drug
therapy were made along the way. His antihypertensive medication had
been altered several times; captopril was administered at a dose of 50
mg twice daily for one year preceding admission. His skin condition
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worsened during this period of followup; cutaneous thickening ex-
tended progressively, involving his shoulders and trunk. He was given
a one-year trial of D-penicillamine, 1500 mg daily. Although the patient
believed that his skin softened during the treatment period, D-penicil-
lamine administration had to be stopped because of neutropenia; the
white blood cell count became normal with discontinuation of the agent.
The serum creatinine rose steadily, and control of hypertension became
increasingly difficult.
Physical examination on this admission again revealed the stigmata of
scleroderma. His extensively thickened skin was taut, and had a
"hidebound" appearance. He had difficulty opening his mouth because
of tight puckering, and he was breathless at rest with a respiratory rate
of 30 breaths/mm. His blood pressure was 180/106 mm Hg and his
temperature was 98.2°F. Residual left-sided hemiparesis was present.
His medications on admission comprised captopnl, 50 mg twice
daily; nifedipine, 40 mg twice daily; atenolol, 50 mg daily; alpha-
methyldopa, 500 mg twice daily; and furosemide, 40 mg daily. The
jugular venous pressure was elevated, he had bilateral pitting edema of
the legs, and sinus tachycardia was present (98/mm with an S3 gallop).
Auscultation of the lungs disclosed pulmonary congestion.
Laboratory data confirmed advanced renal failure. The serum creat-
mine was 7.2 mgldl (versus 3.2 mg/dl 3 months earlier); BUN, 150
mg/dl; hematocrit, 32%; white blood cell count, 16,300 mm3, with a
leftward shift in the differential; platelet count, 210,000 mm3; serum
sodium, 141 mEq/liter; potassium, 6.2 mEq/liter; chloride, 98 mEq/liter;
carbon dioxide, 12 mEq/liter; calcium, 8.9 mg/dl; phosphate, 6.4 mg/dl;
and erythrocyte sedimentation rate, 46 mm/hr. Arterial blood pH was
7.22; 902, 88 mm Hg; and pCO2, 27 mm Hg. The urinary output was
scant and concentrated; the specific gravity was 1.030; the protein
content was 120 mg/dl; and numerous granular casts and one red blood
cell cast were seen on urinary microscopy. A chest radiograph con-
firmed pulmonary edema with infective consolidation in the left base.
The patient was transferred to the nephrology service. Diuretic
therapy was intensified (furosemide, 80 mg intravenously twice daily);
bicarbonate infusions were given for correction of metabolic acidosis;
and broad-spectrum intravenous antibiotics were administered. He
became more alert over the next 2 days, and his neurologic signs
resolved virtually completely. A percutaneous renal biopsy showed
marked interlobular arterial hyperplasia with prominent subendothelial
mucoid intimal proliferation and areas of fibrinoid necrosis affecting the
intima of many vessels. The vascular lumina were grossly narrowed
with occasional examples of total occlusion. Areas of concentric
fibrocellular collagen accumulation with perivascular fibrosis were
present. Tubular atrophy and glomerular collapse were observed sec-
ondary to ischemia. Immunofluorescence studies were positive only for
fibrin in both affected arterioles and parts of some glomeruli. These
pathologic changes were regarded as typical of scleroderma kidney
(Fig. 1).
He tolerated the biopsy procedure well, but his condition continued
to deteriorate. The urinary output remained poor, and his renal failure
accelerated. The serum creatinine was 14.2 mg/dl; the serum potassium
rose to 6.9 mEq/liter, and metabolic acidosis recurred. Emergency
hemodialysis therapy, with vigorous ultrafiltration, was undertaken
utilizing subclavian venous access on the 6th hospital day. Hemodial-
ysis was repeated daily thereafter for the next 3 days. Despite some
improvement clinically and biochemically, his pneumonia worsened
and he succumbed just prior to the 5th planned dialysis session. An
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Case presentations
Fig. 1. Percutaneous renal biopsy tissue from
Patient I with diffuse scleroderma. a
Representative arteriole showing gross
narrowing of the vascular lumen and marked
subendothelial mucoid intimal proliferation
(hematoxylin and eosin). b Massive concentric
fibrocellular collagen accumulation and
perivascular fibrosis in another blood vessel
(fibrin stain).
autopsy confirmed the widespread cutaneous and visceral changes of
diffuse scleroderma.
Patient 2. A 40-year-old woman was referred to the Emergency
Department of the Mater Misericordiae Hospital with severe hyperten-
sion and a one-week history of blurred vision, nausea, and frontal
headaches. On arrival, her blood pressure measured 190/138 mm Hg
and she immediately was given nifedipine, 10 mg sublingually, and
propranolol, 80 mg orally.
Her medical history was relatively uneventful. She had undergone a
routine cholecystectomy 10 years previously, and she had had 4
full-term pregnancies. Her last one, 5 years prior to this episode, was
complicated by hypertension in the last trimester; her blood pressure
returned to normal following delivery. She had had Raynaud's phenom-
enon for 5 to 6 years, which had worsened in the previous 3 years.
Physical examination disclosed widespread telangiectasia affecting
her upper torso and face. She weighed 47 kgs. Her fingertips appeared
tapered. She was fatigued and anxious but fully oriented to time and
place. The pulse rate was 100 beats/mm and regular. Both radial pulses
were difficult to palpate. Her respiratory rate was 26 breaths/mm and
her temperature was 98°F. Funduscopic examination showed severe
hypertensive retinopathy with bilateral papilledema, arteriolar narrow-
ing, arteriovenous nicking, splinter hemorrhages, and soft exudates.
The apical heart beat was displaced just outside the mid-clavicular line,
and a loud second sound was heard in the aortic area.
A grade Il/Vi early systolic murmur was audible in the left paraster-
nal region, and an S3 gallop was present. The jugular venous pressure
was normal. The lungs were clear to auscultation. Abdominal exami-
nation revealed a cholecystectomy scar and striae gravidarum. No renal
artery bruits were heard and there was no edema. Laboratory studies
revealed a hematocrit of 46%; white blood cell count, 9,300 mm3 with a
normal differential; platelet count, 213,000 mm3; BUN, 31 mg/dl;
creatinine, 1.7 mg/dl; sodium, 140 mEq/liter; calcium, 10.4 mg/dl;
phosphate, 4.6 mgldl; and erythrocyte sedimentation rate, 9 mm/hr.
Urinalysis showed a specific gravity of 1.020; pH, 6.0; and 50 mg/dl of
protein. The urinary sediment was clear. A 24-hour urine collection
contained 408 mg creatinine and 530 mg protein; the creatinine clear-
ance was 25 mI/mm.
Renal size was normal on ultrasound examination, and obstructive
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uropathy was excluded. A CT scan of the adrenal glands was normal.
Her blood pressure stabilized with propranolol, 80 mg twice daily;
nifedipine, 20 mg twice daily; and chlorthalidone, 25 mg daily. She was
discharged after 10 days with a blood pressure of 124/80 mm Hg. She
was much improved overall, and her pre-discharge serum creatinine
was 1.4 mg/dl, She was given an appointment for the nephrology
outpatient clinic 3 weeks later.
On the day she was due to attend the clinic, she was again admitted
through the Emergency Department with a blood pressure of 210/150
mm Hg, severe frontal headache, and complete loss of vision in her left
eye. Her renal function had deteriorated markedly; the serum creatinine
was 5 mg/dl and the BUN was Ill mg/dl. Urinalysis disclosed 50 mg/dl
proteinuria, 150 red blood cells/high-power field, and numerous granu-
lar casts. Her husband indicated that she had taken her antihyperten-
sive medications as prescribed but that her condition had appeared to
deteriorate abruptly during the previous 2 days. She was anxious,
extremely distressed, anorectic, and had lost weight.
Changes in her physical examination were evident from her first
admission: hemorrhages were apparent near her left macula; the apical
heart beat was displaced further towards the axilla; the jugular venous
pressure was elevated; wet rales were heard in both lung bases; and
mild pitting edema of the legs was present.
On this second admission, the blood pressure eventually was con-
trolled by the introduction of captopril, 25 mg twice daily; nifedipine, 20
mg twice daily; atenolol, 100 mg twice daily; and furosemide, 40 mg
daily. The blood pressure stabilized at 150/90 mm Hg.
A percutaneous renal biopsy showed severe hypertensive nephro-
sclerosis with a marked degree of intimal thickening due to concentric
layers of fibrocellular tissue and smooth muscle. No changes typical of
vasculitis were noted. Widespread renal tubular degeneration and
several areas of tubular atrophy were present. Proteinaceous casts were
observed in many tubular lumina (Fig. 2).
Immunofluorescent staining of glomeruli was negative. A test for
anti-nuclear antibody was strongly positive at a titer of greater than
1:320 with a finely speckled pattern; an anti-ribonucleoprotein antibody
test also was positive. Anti-centromere antibodies were demonstrated
on chromosome immunofluorescence, A test for anti-Sd 70 was nega-
tive.
A search was initiated for scleroderma-related features. Esophageal
motility studies showed complete absence of peristalsis, with lower
segment spasm. Barium enema revealed a few pseudodiverticulae.
Nailfold capillaroscopy was abnormal, and a Schirmer (tear) test was
positive for dry eyes. Plain radiographs of the hands showed sclerodac-
tyly and minimal soft-tissue calcification. Digital subtraction arch
aortography with views of the renal arteries was normal. Pulmonary
function tests disclosed a normal vital capacity; one-minute forced
expiratory volume was 73% of that predicted.
A diagnosis of scleroderma, CREST variant (calcinosis, Raynaud's
phenomenon, esophageal dysmotility, sclerodactyly, and telangiecta-
sia) was made (Fig. 3). Her renal failure was thought to be due to severe
(malignant) hypertensive nephropathy complicating the CREST syn-
drome.
Despite satisfactory control of the hypertension, her renal function
deteriorated further, and she became overtly uremic. She was trans-
ferred to the National Renal Centre, Beaumont Hospital, and thrice-
weekly hemodialysis was begun. Her course on dialysis was relatively
uneventful, and she received a cadaveric renal transplant 7 months after
beginning dialysis therapy.
Although the transplant functioned satisfactorily at first, she devel-
oped a resistant cellular rejection, which was unresponsive to intrave-
nous methylprednisolone pulse therapy. Biopsy of the graft showed
severe cellular rejection, and she was given a 10-day course of mono-
clonal antibody (OKT3). She gradually regained excellent transplant
function.
At her most recent outpatient review, 21 months following transplan-
tation, her blood pressure was 130/75 mm Hg; the serum creatinine was
1.4 mg/dl; and urinalysis revealed only a trace of protein. Her present
medications comprise: cyclosporine, 250 mg daily; prednisolone, 9 mg
daily; azathioprine, 100 mg daily; nifedipine, 20 mg twice daily; and
enalapril, 5 mg daily. Her facial telangiectasias are more prominent than
before, but she is convinced that her Raynaud's phenomenon has
ameliorated markedly since she received the renal transplant.
Discussion
DR. JOHN F. DoNonoE (Consultant Nephrologist, National
Renal Centre, Beaumont Hospital and Mater Misericordiae
Hospital, Dublin, Ireland): In reviewing scieroderma and scle-
roderma-related disorders, one is struck by the very wide
spectrum of disease that is manifest among individual patients.
The array ranges from benign, localized cutaneous involvement
(morphea) to florid systemic sclerosis with virtual total trans-
formation of normal skin into a leathery body jacket and
involvement of multiple internal organs. The two patients being
discussed today exemplify two extremes of systemic sclerosis;
the first case shows the typical widespread skin involvement
occurring in a progressive manner and culminating in a virtual
hidebound effect; the second case illustrates another classic
type of scleroderma, that which is conveniently described by
the acronym CREST. Both are examples of generalized sclero-
derma; the man had the most severe clinical variant, diffuse
cutaneous systemic sclerosis (dSSc), whereas the woman had
limited cutaneous systemic sclerosis (lSSc). Both patients
showed common scieroderma-associated features, including
prominent hypertension and rapid progresssion to complete
renal failure. In both instances, this progression was relentless
despite appropriate management of hypertension that included
the use of angiotensin-converting-enzyme (ACE) inhibitors.
An in-depth examination of the many scieroderma-related
disorders is beyond the scope of this discussion, so I will only
briefly focus on involvement of organs other than the kidney.
The major emphasis here will be on the sometimes devastating
disruption of renal function brought about by this rare and
fascinating systemic condition. Throughout the presentation I
will take license in using the modern term systemic sclerosis
interchangeably with the more traditional term scleroderma.
Clinical overview
Systemic sclerosis is a generalized disorder of connective
tissue characterized by inflammatory and degenerative changes
that can lead to intense and widespread fibrosis. The skin and
subcutaneous tissues are involved predominantly, and this
involvement can extend to the tendons and muscles. A variety
of internal organs can be affected, including the blood vessels,
gastrointestinal tract, lungs, heart, and kidneys [1—4]. Many
classifications have been proposed, and Table 1 offers one
clinically useful scheme. Patients with widespread skin involve-
ment (dSSc) have the greatest likelihood of visceral involve-
ment. The hallmark of this subgroup is scleroderma extending
to the skin of the trunk, as in the first patient presented today.
The second patient, with limited cutaneous scleroderma (lSSc,
CREST variant), had a minor degree of skin change, which was
confined to the fingers and toes (acral), and face [1, 5].
Scieroderma exclusively involving the skin includes the pre-
dominantly dermatologic conditions known as morphea
(plaquelike, guttate) and linear scleroderma (en coup de sabre).
These localized forms of scleroderma usually occur in the
second and third decade and are more common in females.
They generally carry a benign prognosis, and after a few years
the lesions tend to soften spontaneously. By definition, visceral
involvement in this variant is a rarity. Linear scieroderma
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Fig. 2. Percutaneous renal biopsy tissue from
Patient 2 with CREST variant scleroderma. a
Arteriole showing the classic changes of
malignant hypertension with a marked degree
of intimal thickening due to typical "onion-
skin" concentric layers of fibrocellular tissue
and smooth muscle. Stains for fibrin were
negative (toluidine blue stain). b Areas of
disruption of the elastic lamina in another
arteriole (elastic stain).
occurs as a streaky lesion of the extremities, forehead, or scalp,
and can cause disfiguring asymmetry of the face. With limb
involvement, scieroderma (en bande) can cause shortening and
contractures [61.
Several syndromes overlap with scieroderma, including
mixed connective tissue diseases (MCTD). Patients with these
syndromes can have features of classic autoimmune-mediated
conditions (rheumatoid arthritis, systemic lupus erythemato-
sus) in addition to scierodermatous skin involvement, Ray-
naud's phenomenon, and dry eyes and mouth (sicca complex)
[7]. Alternatively, these latter features can coexist with evi-
dence of systemic vasculitis or dermatomyositis/polymyositis
(Fig. 4). It is evident that these descriptions, based primarily on
clinical constellations, might or might not be useful. Prognosis,
as expected, depends on the extent of visceral involvement.
Various toxins have been implicated as causes of chemically
induced scieroderma-like conditions. One such example is the
notorious toxic oil syndrome, in which ingestion of aniline-
denatured rapeseed oil serves as a source of free oxygen
radicals. These agents cause endothelial damage with conse-
quent cycles of vascular injury and repair, which ultimately
results in cutaneous fibrosis in the chronic stage. Corticoste-
roids have proved useful in the acute phase of the syndrome,
which occurred in epidemic proportions and affected as many
as 6,000 patients in Spain in 1981 [8, 9].
Silica (gold and coal mining) [101, therapeutic adjuvants
(silicone breast implants) [11, 121, and various drugs (bleomy-
ci pentazocine, carbidopa) have been implicated in the cau-
sation of scieroderma-like disease [13]. Chronic graft-versus-
host disease following bone marrow transplantation can give
rise to similar scieroderma-like skin changes with sicca complex
[14—16]. This reaction can progress and cause widespread
vascular injury with internal organ involvement analogous to
that of classic generalized scleroderma.
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Fig. 3. Compilation of the clinical features of
limited cutaneous scieroderma (CREST
variant). C shows extrusion of calcific
material from the finger pulp with surrounding
chronic inflammation. The hand radiograph
shows extensive areas of soft-tissue
calcification. R is an example of severe
Raynaud's phenomenon. The patient's left
forefinger was amputated. The right hand
shows the marked pallor due to intense
vasospasm of the fingers. E Gastrografin
swallow shows a dilated, aperistaltic
esophagus with early stricture formation of
the esophageal sphincter due to reflux
esophagitis. S shows sclerodactyly and T the
facial telangiectasias prominent in the pen-
orbital, cheek, and chin regions in Patient 2.
(R, S, reproduced by permission of Dr. C. M.
Black, The Royal Free Hospital, London.)
Diffuse fasciitis with eosinophilia (DFE), another scleroder- ophilia. Abnormal tryptophan metabolism has been docu-
ma-like condition of unknown cause, affects men more corn- mented [18] and, although the condition responds to modest
monly [171. The involvement is confined to the skin with sparing doses of corticosteroids, spontaneous remission after several
of the face. The acute stage involves striking peripheral eosin- years in untreated individuals is also common [17].
1
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Table 1. Classification of scieroderma
1. Generalized scieroderma (systemic sclerosis)
Diffuse cutaneous
Limited cutaneous (CREST syndrome)
Localized scleroderma
Morphea (isolated plaques or confluent)
Linear ("en coup de sabre")
2. Scleroderma-associated syndromes
Mixed connective tissue disease ("overlap")
"Lupudermalsclerolupus"
Sclerodermatomyositis
SjOgren's syndrome
Primary biliary cirrhosis
Inherited
Progeria
Tumor-associated
Carcinoid syndrome
Bronchoalveolar carcinoma
3. Scleroderma-like syndromes
Environmental/occupational/chemical
Vinyl chloride monomer (plastics industry)
Silica (gold/coal mining)
Vibrating tools ("jackhammer disease")
Toxic oil syndrome (Spain)
Silicone/paraffin implants (adjuvant disease)
Drug-induced
Bleomycin, cis-platinum
Pentazocine, carbidopa
Tryptophan
Immunologic
Chronic graft-versus-host disease
Amyloidosis
Unknown
Diffuse fasciitis with eosinophilia (DFE)
Pat ho genesis
Scleroderma is characterized by uncontrolled and usually
irreversible proliferation of connective tissue. Widespread in-
jury to blood vessels accounts for the multisystemic pattern of
involvement [3, 4, 19—23]. End-organ damage progresses
through the classic phases of inflammation, fibrosis, and con-
sequent atrophy. The primary pathogenetic mechanisms in
scleroderma have yet to be fully characterized, but some
important and plausible mechanisms have been formulated.
These include abnormal control of vasomotor tone; abnormal
collagen production by vascular cells and fibroblasts; abnormal
autoimmunity; and finally, damage to endothelial cells. The
most likely scenario is that all of these mechanisms contribute
to a greater or lesser extent in individual cases.
Vasospasm is an integral part of virtually all forms of sys-
temic sclerosis, as evidenced by the universality of Raynaud's
phenomenon in these patients [19, 20, 24]. The first patient
presented today had to quit his job because of severe
Raynaud's. Evidence also suggests that the vasospasm is not
confined to digital or pedal blood flow but that it also can affect
the blood supply to other organs, including the kidney [25, 26],
the coronary circulation [27—29], and the lung [30, 31].
Excess levels of circulating renin, which have been docu-
mented consistently, probably occur secondary to renal hypo-
perfusion [32] but also can derive directly from vascular smooth
muscle cells [33]. In a vasculature primed by renin-angiotensin
excess, intense vasospasm can follow stimuli such as cold
exposure and physical or emotional stress, and can occur after
commonplace stimulants such as caffeine ingestion or cigarette
smoking.
Fig. 4. Schematic representation of various connective tissue "over-
lap" diseases. SLE = systemic lupus erythematosus.
Excessive formation of collagen, the most plentiful protein
constituent of connective tissue, is a hallmark of scleroderma.
The overproduction of collagen is fibroblast-derived; this find-
ing has been confirmed in tissue culture of fibroblasts from
patients with scleroderma [34, 35]. The precise triggers in-
volved in the abnormal fibroblast function are unclear, but
evidence suggests that cytokines released from activated mast
cells contribute to this alteration [36, 37]. Douvas showed that
collagen genes in scleroderma recognize topoisomerase I (Sd-
70), a nuclear enzyme, whereas genes from control patients
display no such recognition [38]. These observations could
point to a molecular genetic abnormality that gives rise to
excess collagen production, the primary event in scleroderma.
Agents directed toward a reduction in collagen gene transcrip-
tion (gamma interferon) point the way to potentially revolution-
ary treatments for scleroderma [39].
Other approaches aimed at reducing excess fibroblast colla-
gen production include the use of mast cell stabilizers (cro-
molyn sodium, ketotifen). The efficacy of these agents has been
confirmed in animal studies utilizing the tight-skinned mouse
(Tsk) model [37] as well as in clinical investigations [40]. The
use of D-penicillamine is the more traditional method of inter-
fering with collagen metabolism. This drug blocks aldehyde
groups involved in the cross-linkages of insoluble, mature
collagen. It also might stimulate the breakdown of insoluble
collagen and inhibit new collagen synthesis [41]. Its efficacy in
softening previously thickened skin has been confirmed in
blinded clinical trials [42].
Several autoantibodies have been identified in patients with
scieroderma. These findings suggest that autoimmunity is a
possible basis for the disorder. Most patients have positive
antinuclear antibodies showing a finely speckled pattern. When
a specific substrate (HEP-2 cell) is employed, the yield for
1. "Lupuderma'
2. Mixed connective tissue disease
3. "Scterodermatomyositia"
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positive antinuclear antibody exceeds 70% in patients with
scieroderma. Segregation of nuclear antibodies into antitopo-
isomerase I (ScI-70) or the anticentromere antibody produces a
degree of specificity for various scieroderma subgroups; Scl-70
is a marker for diffuse cutaneous disease; the anticentromere
antibody is a relatively specific marker (>70%) for limited
cutaneous scleroderma (CREST syndrome) [28,43, 44].
In attempting to unify these hypotheses of pathogenesis, one
can postulate that antibodies directed against cellular nuclear
material alter the process of gene transcription and thereby
facilitate abnormal genetic control of collagen formation.
Whether autoantibodies play a primary or secondary role in the
causation of scieroderma is unknown, however. Measures
aimed at reducing these autoantibodies (corticosteroids, immu-
nosuppressive agents, plasmapheresis) have not been uniformly
successful clinically [45—47].
Direct damage to the endothelial cell lining of blood vessels
has been postulated as a significant pathogenetic factor in
scleroderma. Leakiness of these damaged vessels could acti-
vate interstitial fibroblasts to produce excess collagen [23, 48].
Exposure of the internal elastic lamina following destruction of
the endothelial cell lining can cause increased platelet accumu-
lation and would fit with the demonstration of excess circulating
platelet aggregates in patients with scleroderma [49]. These
activated platelets release platelet-derived growth factor
(PDGF) and fibroblast growth factor, as well as known vasoac-
tive substances such as serotonin and histamine [50]. This
observation has stimulated the use of antiplatelet agents
(dipyridamole, aspirin) to decrease PDGF but with little if any
clinical benefit.
Similarly, vasodilator therapy with nifedipine, although ef-
fectively lowering the level of circulating platelet aggregates, is
of proven clinical efficacy only in Raynaud's phenomenon; the
drug's usefulness in scieroderma is as yet uncertain [51, 52].
Endothelin, a potent endothelial cell-derived vasoconstrictor
peptide, has been the focus of recent attention [53—56]. This
peptide might be the locally derived substance that causes
intense and prolonged vasoconstriction and thus could assume
an important pathogenetic role in scleroderma. Again, how-
ever, we cannot be certain whether its action is primary or
secondary to the other mechanisms I already described.
How can we summarize the various mechanisms in the
pathogenesis of scieroderma? Each mechanism probably plays
its own part to a greater or lesser extent in determining the
differing expressions of scieroderma and the markedly contrast-
ing degrees of severity. Exposure to various chemicals, toxins,
and drugs—most notably anticancer agents—could cause direct
endothelial cell injury or more indirectly could injure cellular
nuclear material and give rise to the production of autoantibod-
ies. However, these chemicals also might stimulate fibroblast-
derived collagen production. The most notorious example of
this type of toxin exposure occurred in Spain in 1981, as I
mentioned.
In contrast, scleroderma associated with the use of therapeu-
tic adjuvants, especially silicone or silicone/paraffin implants
for breast augmentation, might arise from a chronic disorder of
autoimmunity [11], a disorder analogous to that in animal and
human examples of chronic graft-versus-host disease [14—16].
In patients receiving bleomycin and cis-platinum for the treat-
ment of gonadal cancers, scleroderma-like syndromes with
prominent interstitial lung disease progressing to pulmonary
fibrosis have been described [13]. The mechanism of disease in
this setting probably is excessive collagen production. Cultured
skin fibroblasts from a patient who received bleomycin and
developed a typical sclerodermatous syndrome synthesized
increased amounts of collagen [13]. In the same study, the
addition of bleomycin to fibroblast cultures from normal skin
also stimulated collagen production. This overactivity subsided
when bleomycin was removed.
Epidemiology
Systemic sclerosis is a rare disorder. The condition affects all
races. The reported incidence in various studies ranges from a
low of 2.7 per million to a high of 12 new cases per million of the
population per year [57, 58]. Like the other connective tissue
disorders, systemic sclerosis carries a strong female preponder-
ance of greater than 3:1; during the childbearing years, the ratio
soars to 15:1 [57]. These striking ratios showing dominant
female incidence underscore the suggestion that hormonal
factors make a noteworthy contribution to the initiation or
promotion of the pathologic processes involved.
The prevalence of systemic sclerosis is approximately 10
times greater than the incidence, at approximately 100 per
million of the population [59]. The prevalence of systemic lupus
erythematosus (SLE), the commonest of the connective tissue
diseases, is four times greater, with a prevalence (both sexes
combined) of 400 per million [60]. Finally, incidence and
prevalence for the connective tissue disorders are only a
fraction of those reported for the major rheumatic disease,
rheumatoid arthritis, which has an annual incidence of 670 new
cases per million, and a prevalence as high as 10,000 per
million, or 1% of the population at large [611.
Whereas genetic associations have been described in both
rheumatoid arthritis and SLE, a genetic predisposition is only
weakly discernible in systemic sclerosis. The disease has been
associated with HLA antigens DR3 and DR5 [62, 63], and an
increased prevalence of antinuclear antibodies in seemingly
unaffected family members has been reported [3, 621.
The natural history and prognosis of systemic sclerosis varies
substantially, and a number of important prognostic "risk
factors" have been identified. These include male gender,
extent of skin involvement (particularly truncal scieroderma),
and most important, the presence of renal disease [58, 64-66].
In general, the overall cumulative survival rate at 5 years is 60%
and at 10 years is 42% [58]. Better survival figures, as expected,
are reported for patients with limited cutaneous scleroderma
(CREST variant) than for those with diffuse disease (50%
versus 83% at 5 years, and 28% versus 71% at 10 years) [58].
Patients with renal involvement at the time of diagnosis of
systemic sclerosis fared abysmally, with 100% mortality at
5-year followup. Significant involvement of other organs, in-
cluding the heart and lungs, was almost as adversely prognostic
as was renal involvement.
Clinical features
Extrarenal manifestations. Although my focus in this Forum
is on the renal involvement associated with scleroderma, for
background and completeness I will mention some of the more
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relevant general features of the disease. Raynaud's phenome-
non, a reversible feature of peripheral vascular ischemia, pre-
dominantly affects the fingers but can also involve the toes,
coronary arteries [27, 671, lungs [30, 31], and kidneys [25].
Observation of the fingers shows a triphasic reaction: they
initially turn white, then become cyanosed, and become quite
red and hyperemic during the re-warming phase. Raynaud's
phenomenon, the presenting feature of many connective-tissue
diseases, is not unique to systemic sclerosis. When the phe-
nomenon has been present for years, patients with systemic
sclerosis can infarct areas of the fingertips with atrophy of the
pulps. In this situation, radiographs sometimes show resorption
of the terminal phalanges; in the CREST variant, extrusion of
small calcific concretions occurs through ulcerated and in-
flamed skin. These features of chronic Raynaud's can be the
most disabling aspect in an individual case of systemic sclerosis
and often requires repeated surgical intervention for drainage of
pus or for amputation. A bedside test of considerable value is
nailfold capillaroscopy utilizing an ophthalmoscope and a drop
of mineral oil. This test can reveal significant abnormality of
capillaries with dilation, deformation, and areas of capillary
depletion [24]. Again, these capillary changes are not confined
to patients with scleroderma, but these alterations do occur in a
higher proportion of patients (82%) when compared with pa-
tients with mixed connective tissue disease (54%). These
changes are rarely seen in SLE (2%) despite the presence of
Raynaud's phenomenon.
Vascular changes in the skin with dilation and deformity of
surviving capillaries cause the characteristic telangiectasias
seen in the face and upper torso. The ischemic skin of the
fingers becomes thickened, fibrosed, and adherent; these
changes produce tapered fingertips, sclerodactyly, Progressive
extension of these areas of skin involvement to the arms, face,
and trunk produces the hidebound appearance of late, diffuse
cutaneous scieroderma. Facial involvement makes the nose
appear pinched and provides the typical pursed-lip appearance
of the mouth. These changes are sometimes so severe that some
patients have difficulty opening their mouth. It is also known
that these skin alterations are not always completely irrevers-
ible, and over many years the skin sometimes softens sponta-
neously. This fact makes studies of the efficacy of various
therapeutic interventions quite difficult; clinical trials require
large numbers of patients treated in a double-blind fashion. Skin
biopsy taken during the indurated phase reveals disappearance
of the sweat glands and hair follicles, and marked thickening of
the dermis due to gross collagen excess.
Musculoskeletal structures (joints, tendons, and muscles) can
be involved in the widespread sclerodermatous process. Ten-
dinitis can progress to contractures involving the knees and
distal joints. Muscle involvement can occur due to chronic
inflammatory cell infiltration, with subsequent atrophy and
fibrosis. These changes usually are most prominent around the
shoulder and pelvic girdles.
Abnormal esophageal function is the commonest form of
visceral involvement in systemic sclerosis [2, 3]. Approxi-
mately 70% of patients experience esophageal dysfunction with
the attendant classic symptoms of nighttime regurgitation due
to reflux of gastric juice. This condition can progress to distal
esophagitis and eventual esophageal stricture formation with
dysphagia. Barium swallow and esophageal manometry reveal
abnormal, disordered peristalsis, reflux, and esophageal dila-
tion. Also apparent is atrophy of the muscle layers of the
esophagus and markedly diminished tone of the lower esopha-
geal sphincter.
The process can involve the small intestine and give rise to
abnormal motility with secondary bacterial overgrowth and
malabsorption syndrome. Extreme degrees of intestinal in-
volvement can cause complete absence of peristalsis, gross
distension, and volvulus [2, 3]. In the large bowel, the lumen
can distend markedly; multiple pseudodiverticulae can be seen
on barium enema. Perforation of the large intestine can occur
consequent to infarction or obstruction.
Pulmonary function tests can reveal a mixture of restrictive
and obstructive changes with ventilation/perfusion mismatch-
ing. Further, diminished diffusing capacity can be present. One
of the most ominous developments is that of diffuse interstitial
pulmonary fibrosis, which usually starts in the lower lobes and
gradually spreads to involve the entire lung fields [68]. Intimal
proliferation affects the smaller pulmonary arteries and gives
rise to pulmonary hypertension. Patients with the CREST form
of systemic sclerosis are more prone to develop pulmonary
hypertension and, later, right heart failure [69].
Involvement of the pericardium can be transient or chronic
[68]. However, actual fibrotic change affecting the myocardium
is far more ominous and can result in refractory congestive
cardiac failure due to ischemic cardiomyopathy [29, 67]. In-
volvement of the cardiac conduction system can cause arrhyth-
mias and sudden death [70]. A summary of these extrarenal
features of scleroderma is provided in Figure 5.
Renal disease. Renal disease has long been recognized as the
most dangerous complication of systemic sclerosis. Formerly
almost an inevitably fatal development, progressing through
acute or chronic renal failure, it is the commonest mode of
death in these patients [25, 64, 71].
First described in 1836 by Fantonetti and termed Skiero-
derma, the emphasis in that and subsequent reports focused
primarily on the dermatologic manifestations of the condition.
The concomitant presence of renal disease was deemed a
chance association [72]. Indeed, it remained so until the early
l950s, when Moore and Sheehan provided detailed clinical and
pathologic findings from the kidneys of 3 patients with sclero-
derma who died of uremia [73].
Estimates of the incidence of renal involvement in sclero-
derma vary widely, depending on which markers of renal
disease are employed and whether the estimates are based on
community, hospital, or autopsy studies. Utilizing the extreme
of severe, unrelenting renal failure, the approximate incidence
is 10%. If more subtle markers of renal dysfunction are sur-
veyed, such as proteinuria, reduction in glomerular filtration
rate, or hypertension, then the incidence figure rises to approx-
imately 50%. When pathologic renal change at autopsy is used
as the criterion, the incidence of renal disease can be as high as
80% of scleroderma patients [3, 20, 25). At least one of these
traditional markers (proteinuria, hypertension, or renal func-
tional impairment) was present in 45% of 210 patients studied
by Cannon et al [25] (Table 2). In another large series, protein-
uria occurred in 109 of 727 patients (15%) and renal failure was
present in only 3% [19]. Yet another study involving 309
patients reported an incidence of approximately 5% with sub-
stantial proteinuria [641. These markers of renal involvement
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Fig. 5. Histographic representation of the incidence of the major
extrarenal manifestations in patients with diffuse versus limited
(CREST variant) scieroderma.
are nonspecific, but they do provide at least a rough estimate of
the frequency of scieroderma-related renal disease.
Scieroderma renal crisis (SRC) is the distinct, life-threatening
complication in patients with systemic sclerosis. It most often
develops during the first 5 years after diagnosis [74] and is
heralded by rapidly progressive renal failure during the preced-
ing weeks or months. The clinical features are predominantly
those of severe hypertension, with headaches, visual distur-
bances, and acute left-ventricular failure. Renal blood flow and
glomerular filtration rate are decreased, azotemia rapidly
progresses, and the urinalysis is active, revealing proteinuria,
microscopic hematuria, and granular casts. As a rule, measure-
ments of peripheral plasma renin levels are markedly elevated
[25, 32, 74]. The renin level can rise acutely and extremely, but
it is as yet unclear whether this elevation is a primary phenom-
enon or whether it occurs secondary to renal ischemia; the
latter possibility seems more likely. Traub and colleagues
measured renin levels in 13 of 68 patients one week to one year
prior to the development of SRC. None had significantly
elevated renin levels [74]. In a further attempt to dissect out the
role of renin, Kovalchik and coworkers performed renal biopsy
in 9 patients with scleroderma and normal renal function [26].
Plasma renin was elevated in 3 of 4 patients with recognizable
vascular changes on biopsy, and was normal in the 5 patients
who lacked such changes. Renin levels changed in response to
a cold pressor challenge only in patients with biopsy-demon-
strable vascular changes.
It is tempting to speculate that a form of functional Raynaud's
phenomenon, perhaps induced by cold exposure or other
stimuli, is superimposed on an already injured renal microvas-
culature, and that this combination sets in motion the cata-
strophic cascade of events culminating in SRC [74]. In a
sequence of events commonplace in various forms of vascular
renal injury (including malignant hypertension), spasm of intra-
renal arterioles causes ischemia of the juxtaglomerular appara-
tus and stimulates renin release. This, in turn, increases the
production of angiotensin II and causes further severe vasocon-
striction; the vicious cycle continues.
Renal biopsy and autopsy evidence confirms the vascular
abnormalities that affect the small interlobular and arcuate
vessels with intimal hyperplasia, fibrinoid necrosis, and "down-
stream" ischemia. There is accumulation of a mucoid ground
substance with marked proliferation of intimal cells. The inter-
Table 2. Incidence of "markers" for renal disease in systemic
sclerosisa
n = 210
Proteinuria 36%
Hypertension 24%
Azotemia 19%
Malignant hypertension (SRC)' 7%
a 45% of patients had one or more of the markers. (From Ref. 25.)b Abbreviation SRC is scleroderma renal crisis.
nal elastic lamina may be damaged, allowing the migration of
collagen-producing cells into the intima, media, and further into
the perivascular interstitium. Fibrous thickening of the adven-
titia and fibrosis of the peri-adventitial tissues ensue, giving rise
to the unique vascular lesion of scleroderma renal injury [20, 26,
48]. Changes in the glomeruli comprise thickening of the
basement membrane and progressive glomerulosclerosis. Im-
munofluorescence studies of affected glomeruli show nonspe-
cific changes primarily consistent with ischemic glomerular
injury. Immunoglobulin (1gM), complement, and fibrinogen
deposits have been reported, and, in a few cases, antinuclear
antibodies have been eluted from biopsy material [48, 75]. In a
series of 9 patients, Kovalchik et al found C3 deposition in
blood vessels and glomeruli, even in the subgroup of 5 patients
in whom vascular change was not apparent on biopsy [261. This
finding suggests that the presence of C3 is merely incidental.
Before the introduction of the angiotensin-converting-en-
zyme inhibitors, survival after renal crisis was minimal, with
most patients dying within one to 3 months [25, 64, 74]. The
availability of ACE inhibitors in the late 1970s revolutionized
the prognosis for patients with SRC. The first report detailing
the reversal of SRC appeared in 1979 [76]; this now-classic
account has been substantiated by others [74, 77, 78]. In a
recent study of 108 patients with SRC, the comparative one-
year survival was only 18% for patients treated prior to the
availability of ACE inhibitors but 76% for those who received
the drugs [77]. Despite these impressive reports, however,
several patients have received ACE inhibitors and attained
satisfactory blood pressure control but still have developed
complete renal failure; witness both the discussion cases today.
Steen et al observed progression to renal failure or death in 24
of 55 patients who received ACE inhibitors [77]. In the 53
patients who did not receive these agents, a poor outcome was
observed in 49 patients (92%). It is unclear why adequate ACE
inhibition cannot rescue almost one-half of the targeted pa-
tients. Perhaps some of these patients had unduly advanced
disease when ACE-inhibitor therapy was initiated. This possi-
bility would be consistent with the clinical presentation of the
first patient, but one would predict that the second patient
would have fared better. The literature does contain other
reports of the failure of ACE inhibition to reverse or forestall
progression of renal failure in SRC [79, 80].
Most of the early reports featured the use of captopril for
ACE inhibition, as it was the only orally active agent available.
Some patients with systemic sclerosis receive D-penicillamine,
which contains sulfydryl groups, as does captopril. The sulfy-
dryl group has been implicated as a cause of some captopril-
associated and D-penicillamine-associated side effects [81]. It is
therefore preferable that these two drugs not be used together.
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The availability of alternative ACE inhibitors (enalapril, lisino-
pril) has increased the range of agents available that lack the
sulfydryl group.
Reduction in skin thickening after reversal of SRC has been
reported [25, 74, 79]. These reports have given rise to the
tantalizing prospect that the captopril sulfydryl group acts in the
skin just as D-penicillamine does, but this effect has not been
fully substantiated [82]. To study this penicillamine-like effect
of captopril, Martin et al administered captopril to patients with
rheumatoid arthritis. The drug appeared to be of value both
clinically and in the suppression of laboratory signs of rheuma-
toid disease activity [83]. Captopril has less potent effects than
does D-penicillamine. To test whether the sulfydryl group of
captopril or its ACE inhibitory property was responsible for its
efficacy in rheumatoid arthritis, Jaffe gave enalapril to patients
with rheumatoid arthritis who had previously responded well to
D-penicillamine [84]. Enalapril offered no benefit either in
clinical or laboratory parameters of disease. This report sup-
ports the hypothesis that the sulfydryl group is the active
component responsible for anti-rheumatoid activity [84].
The management of SRC entails no contraindication to the
additional use of other antihypertensive agents, including beta
blockers, calcium-channel blockers, and vasodilators. Diuret-
ics, because of their ability to stimulate renin levels, are best
avoided. The acute management of malignant hypertension
might require parenteral therapy with nitroprusside infusion,
but only for relatively short intervals because of the hazard of
thiocyanate accumulation in renal failure.
Irreversible SRC or more slowly developing complete renal
failure in systemic sclerosis requires some form of renal re-
placement therapy. This can take the form of either hemodial-
ysis, continuous ambulatory peritoneal dialysis (CAPD), renal
transplantation, or a combination of these. Hemodialysis can be
complicated by (1) the difficulty of fashioning and maintaining
suitable vascular access and (2) the inherent hemodynamic
instability that can be present in these patients [85]. Two
relatively small series of patients maintained with chronic
dialysis have been reported [86, 87]. In the 1978 report by
LeRoy and Fleischmann, 17 patients were treated with either
peritoneal dialysis or hemodialysis, but 7 patients had bilateral
nephrectomy for uncontrollable hypertension [86]. The compar-
ative mortality rate showed that only 10% of patients survived
beyond 6 months without nephrectomy, whereas 43% survived
longer than 6 months following nephrectomy. As I already
mentioned, the use of ACE inhibitors should completely obvi-
ate the need for nephrectomy [77]. The recent report from the
Forum of End-Stage Renal Disease (ESRD) Networks for the
years 1983—1985 encompasses the largest series to date: 311
patients with scleroderma-induced ESRD [88]. Females ac-
counted for 72% of the total number. Of the 311 patients, the
majority (79%) were treated initially by hemodialysis, 20% by
CAPD, and in only 1% was cadaveric transplantation per-
formed ab initio. Overall, patients with systemic sclerosis had
the worst survival rate, 33% at 3 years, as compared with a
survival rate of 71% at 3 years for patients with lupus nephritis
in the same study. A search of the most recent data (1989) from
the European Dialysis and Transplant Association (EDTA)
Registry disclosed a total annual listing of almost 29,000 new
end-stage renal disease patients (personal communication, Sel-
wood N, EDTA Registry, 1991). This number of new patients is
remarkably similar to that recorded in the Forum of Networks
Report (28,944 in 1985). But the number of patients with
scleroderma was substantially lower in Europe than in the U.S.,
43 compared with 115 (Table 3). The incidence of SLE-induced
ESRD in the two populations was closer: 228 European patients
versus 343 from the U.S. Does this rate indicate a lower
incidence of renal failure due to scleroderma in Europe, or are
the patients referred less frequently? Using these figures, and
taking the island of Ireland as a whole, we can anticipate seeing
only 4 cases of scleroderma renal crisis each year and a single
case of scleroderma-induced ESRD each 2 to 3 years. This
predictable rarity was reflected in a retrospective survey of all
the renal units in Ireland, in which only 5 such patients,
including the 2 patients discussed today, were discovered.
Like hemodialysis, CAPD also has some potentially adverse
features in patients with scieroderma. These include (1) sclero-
sis of the peritoneal membrane, (2) diminished blood flow due to
Raynaud's phenomenon of the peritoneal vasculature, and (3)
exit site problems (poor healing, infection). However, CAPD
has been successfully employed in several patients [88, 89]. In
the report by Copley and Smith, Raynaud's phenomenon of the
hands was triggered by the use of unheated dialysate. In
addition, peritoneal clearances and pulmonary function de-
creased seasonally from summer to winter [89]. Altered perito-
neal permeability has been described in patients with systemic
vasculitides, and the reduced peritoneal clearances in patients
with scleroderma have been improved by the use of intraperi-
toneal isoproterenol [90]. This maneuver suggests a reversible,
functional, Raynaud-type vasospasm of peritoneal blood ves-
sels.
Successful renal transplantation for scieroderma-induced re-
nal failure was first reported by Richardson in 1973 [85]. Several
other reports have appeared since [86—88, 91], including at least
one with well-documented recurrence of systemic sclerosis in
the transplanted kidney [75]. The overall paucity of cases
precludes substantial comparative reports on how these pa-
tients fare overall compared with other groups undergoing renal
transplantation for ESRD. But the patients with scleroderma
probably do worse, given the gravity of their underlying condi-
tion.
Recovery of renal function sufficient to allow patients to
become dialysis independent has been amply documented in
scleroderma-induced renal failure with varying degrees of fre-
quency. In the large series of 311 patients with scieroderma-
induced ESRD reported by Nissenson and Port, 6.8% of
patients recovered sufficient renal function to achieve dialysis
independence [88]. This figure was the same as for patients with
Henoch-SchOnlein purpura, whereas renal function recovered
in only 3.3% of patients with lupus nephritis [88]. In another
report, 20 patients with scleroderma-induced renal failure re-
quired dialysis for longer than 3 months. Therapy with ACE
inhibitors was continued during their time on dialysis, and 11 of
the 20 patients recovered sufficient renal function to allow
discontinuation of dialysis between 3 and 15 months later [77].
After an average followup of 3 years, these 11 patients had a
mean serum creatinine of 2.1 mg/dl.
Conclusion
Systemic sclerosis, a condition of varying intensity of expres-
sion, continues to present a major therapeutic challenge. A
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Table 3. Systemic sclerosis (scleroderma)-induced ESRD:
Europe versus USA
USA,
Europe, 1989 1985
TotalFemale Male Total
New ESRD 11,788 16,945 28,733 29,000
Systemic lupus 187 41 228 343
Systemic sclerosis 28 15 43 115
USA 1 per 250 new ESRD
Europe 1 per 600 new ESRD
a From European Dialysis and Transplant Registry Data (1991) and
Ref. 88.
sometimes disabling and disfiguring entity, it carries a guarded
prognosis in its fully expressed variant of diffuse cutaneous
systemic sclerosis, and in its most feared complication, sclero-
derma renal crisis and renal failure. However, a watershed in
the management of this disease—the use of ACE inhibitors—
has markedly improved the outlook for these patients.
Questions and answers
DR. JOHN T. HARRINOTON (Chief of Medicine, Newton-
Wellelsey Hospital, Newton, Massachusetts): You mentioned
the role of the renin-angiotensin system in seleroderma renal
crisis, but in recent years we have learned about a new
vasoconstricting microhormone, endothelin. Endothelin levels
are elevated in a number of clinical conditions including hyper-
tension and acute renal failure. Are there any studies of
endothelin levels in SRC? If so, what could we do about the
findings?
DR. DONOHOE: Since its initial description in 1988, a bur-
geoning literature has accumulated concerning the autacoid
endothelin. Displaying 10 times the vasoconstrictor potency of
angiotensin II, endothelin is the most powerful endogenous
vasoactive substance yet described [531. As you mentioned,
elevated circulating levels of endothelin have been recorded in
patients with essential hypertension, with acute renal failure,
and during cyclosporine administration [55, 92—95]. I am un-
aware of endothelin levels having been reported in patients with
SRC, but endothelin is elevated in patients with scleroderma
[96]. It would be tremendously interesting to obtain endothelin
levels in SRC, particularly if one were fortunate enough to
"bracket" an episode. Because renal parenchyma has the
highest concentration of endothelin and the renal vasculature is
extremely susceptible to its vasoconstrictor actions [54, 97, 98],
my speculation is that the elevated baseline endothelin levels in
scleroderma should rise precipitously with the onset of SRC. I
think that elevated endothelin levels are secondary to vascular
endothelial cell damage; this interpretation is supported by the
observation that cyclosporine appears first to injure endothelial
cells and only then to raise endothelin levels [551. My conclu-
sion is that in SRC, an undetermined toxin (or toxins) damages
endothelial cells and adds yet another extremely potent vaso-
constrictor (endothelin) to the multitude of vasoactive sub-
stances already described and further promotes intense renal
vasospasm and ischemia. Whether the administration of endo-
thelin antiserum [94, 95, 99] has a role in the therapy of SRC will
depend on more precise elucidation of the pattern of endothe-
lin's behavior in scleroderma itself as well as in the dramatic
complication of SRC. As an interim research area of potential
relevance, studies of endothelin levels and the effects of endo-
thelin antiserum in renal transplant patients receiving cyclos-
porine would seem worthwhile.
PROF. FINcIs P. MULDOWNEY (Consultant Metabolic Phy-
sicianlNephrologist, St. Vincent's Hospital, Dublin, Ireland):
Clearly, the role of captopril is critical in scleroderma renal
crisis, where fully 82% of patients are dead within one year
without the drug, whereas mortality decreases dramatically to
24% when one uses an ACE inhibitor [77]. Does the beneficial
effect of captopril extend to other vasculitic forms of acute renal
failure? I'm not sure whether this has been reported, but it
would be interesting to have your views. Also I am concerned
about the subset of patients with scleroderma who present with
acute vasculitic renal failure but in whom florid cutaneous
manifestations are not obvious and so the diagnosis of SRC is
missed [100]. Finally, a caveat about the use of ACE inhibitors
in any patient with acute renal failure: dangerous hyperkalemia
can be precipitated by these drugs.
DR. D0N0H0E: We have not routinely used captopril in the
management of other vasculitic forms of acute renal failure,
such as the crescentic glomerulonephritis of Goodpasture's
syndrome or severe lupus nephritis. Traditionally, we use
steroids, immunosuppression, and plasmapheresis in these pa-
tients. But perhaps we should be exploring the potential efficacy
of ACE inhibitors in this dramatic clinical setting. The deciding
point for deploying captopril (or any other ACE inhibitor)
seems to be the concomitant presence of profound hyperten-
sion, almost an invariable feature of SRC, but not commonly a
prominent feature in the other vasculitic states. The specific
diagnosis of SRC in patients lacking an overt history or typical
clinical features of scleroderma (skin changes, acrocyanosis)
almost certainly depends on histologic confirmation by renal
biopsy, not always a straightforward procedure in these criti-
cally ill and severely hypertensive patients. I accept your
comment concerning the propensity towards substantial hyper-
kalemia in ACE-inhibitor-treated patients with renal failure,
and the consequent need for urgent dialysis treatment. This
potential problem has not been emphasized in the series of SRC
patients reported to date.
PROF. J. A. BRIAN KEOGH (Consultant Physician/Nephrolo-
gist, The Meath Hospital, Dublin): Do measures aimed at
reducing various antibody levels in patients with scleroderma
have a favorable impact on the course of the disease? Do
anticoagulants such as heparin, or antiplatelet agents such as
aspirin or dipyndamole, play a role?
DR. D0N0H0E: Your first question is an extremely relevant
one. It raises the issue of the actual toxicity of these various,
well-described antibodies in both the initiation and propagation
of the disease state [28, 43, 441. I am uncertain about assigning
a direct cellular insult to these high antibody titers in vivo. It is
perfectly feasible, through a variety of interventions (immuno-
suppression, plasmapheresis), to markedly lower the circulating
levels of these antibodies [45—47, 101] but disappointingly, in
scleroderma, a clear-cut clinical benefit has not ensued.
Regarding your second question, anticoagulants and anti-
platelet agents, as well as nifedipine, appear more useful in
Raynaud's phenomenon and are of little or no value in sclero-
derma per se [49, 51]. It is of interest that platelet aggregates
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have been found in the serum of patients with scleroderma and
are diminished by dipyridamole and aspirin therapy [49].
DR. HARRINGTON: Is renal disease a prominent feature in
experimental models of scleroderma? If so, it would facilitate
the evaluation of various treatment options such as captopril.
DR. D0N0H0E: Unfortunately it is not. For example, in
chronic graft-versus-host disease and in the tight-skinned
mouse, renal disease is not present despite substantial involve-
ment of the skin and other viscera [14—16]. Thus, it is excep-
tionally difficult to plan the type of prospective evaluations, so
necessary in scleroderma renal disease, that you describe.
Rather we have to fall back on relatively unsatisfactory retro-
spective/historic groupings, such as before and after the era of
captopril availability [77].
DR. OLIVER FITZGERALD (Consultant Rhematologist, St.
Vincent's Hospital): We regularly see patients who have defi-
nite scleroderma but who remain normotensive. Do you think
we should give them ACE inhibitors anyway? Is there evidence
suggesting that this practice can prevent the development of
renal crisis? My second question relates to renal transplantation
in scleroderma: does the disease recur in the transplanted
kidney? Finally, I have a comment in relation to the earlier
question about endothelin. Elevated serum levels of endothelin
have been documented in patients during induced episodes of
Raynaud's phenomenon, and a recent report postulated raised
endothelin levels as one of the causes for the phenomenon
[102].
DR. D0N0H0E: Thank you for that information. Your second
question is the easier one. I am aware of only 2 cases of
recurrence of scleroderma-induced renal disease in a renal
transplant [75, 91]. The better-documented case involved a
living-related graft from mother to daughter; renal histology
was available from the recipient's native kidney, and renal
biopsy tissue came from the transplanted kidney during "acute
rejection" and later from the transplant nephrectomy specimen.
All specimens showed convincing evidence of scleroderma
kidney. The difficulty resides in trying to distinguish the
changes of rejection, particularly acute humoral rejection, from
recurrent disease and to discern hypertensive nephropathy
from scleroderma-induced renal disease. Nonetheless, this one
case is quite compelling and I was convinced by it [75].
Unfortunately, the overall experience of transplantation for
end-stage renal disease in scleroderma is so limited that an
incidence figure for recurrent disease can only be speculative; I
sense it is not a prominent occurrence.
The answer to your first question is more problematic. It is
clear that even normotensive patients with scleroderma can
develop progressive renal disease and renal failure [103]. So
hypertension per se is not a sine qua non for the development of
scleroderma-induced renal disease although, in the majority of
cases, hypertension has been a prominent clinical feature.
It is also worth observing that even with satisfactory ACE
inhibitor therapy for hypertension, not all patients treated
escape the full expression of renal disease and SRC [77, 79], as
in both of the case presentations today. On balance, I tend to
use ACE inhibitors in patients with scieroderma, even at the
risk of causing mild hypotension, and particularly if any evi-
dence of renal involvement (proteinuria, active urine sediment,
renal functional impairment) is present.
DR. DERMOT MURNAGFIAN (Consultant Nephrolo gist, Re-
gional Hospital, Cork, Ireland): Can one distinguish between
patients who will do well with captopril versus those who will
not?
DR. D0N0H0E: Unfortunately not. Patients in whom effective
measures aimed at dampening the renin-angiotensin system are
used generally do better than others. Referring back to the
much-cited paper of Le Roy [86] from the pre-captopril era, we
find that the only patients who did well were the subset in whom
deliberate nephrectomy was undertaken; all other treatment
modalities failed abysmally. The availability of ACE inhibitors
marked a watershed in the management of scieroderma renal
crisis and rendered nephrectomy obsolete [76]. One-year mor-
tality was reduced from 82% to 24%. And yet, as many as 50%
of captopril-treated patients develop renal failure or die prema-
turely [77], a fact borne out by the 2 patients today. Attempts at
classifying scieroderma patients into those who will or will not
do well with ACE inhibition have been largely unsuccessful
despite the availability of a number of intuitively reasonable
discriminatory parameters, such as the presence or absence of
hypertension, renin levels (and, in the future, endothelin lev-
els), or the presence or absence of markers of renal involve-
ment. In general, patients do better with ACE inhibitors than
without, but individual patients differ in their response. The
advice must be to treat them all, to monitor their response, and
to employ dialysis if needed (with continuation of ACE inhibi-
tors). In a minority of patients (less than 10%), return of
sufficient native renal function will allow discontinuation of
dialysis, but it may take as long as 18 months.
DR. MARK LAHER (Consultant Physician/Nephrologist, The
Blackrock Clinic, Dublin): The work of Linz et al in a rat model
of hypertensive hypertrophic cardiomyopathy, utilizing equally
hypotensive doses of various agents, clearly demonstrated that
only an ACE inhibitor (in this instance, ramipril) could prevent
or reduce the cardiac hypertrophy. Even very low, sub-hy-
potensive doses of the ACE inhibitor were capable of producing
this effect [104]. In other words, at least in this experimental
model, the advantages of ACE inhibitors extend beyond their
solely hypotensive actions. My question, based on these obser-
vations, is as follows: Do you think that the benefit of ACE
inhibition in these patients is solely a result of blunting the
renin-angiotensin cascade, or is something else, as yet unmea-
sured, responsible for the beneficial effects observed?
DR. DoNoHoE: Effective measures aimed at reducing or
eliminating the renin-angiotensin axis, initially by deliberate
nephrectomy [86] and later using ACE inhibitors [77, 78, 82],
have had a major beneficial impact on the previously fatal
course of scleroderma renal crisis. But this evidence does not
prove the hypothesis, attractive as it might be, that all this
improvement is due to the renin-angiotensin system. Nephrec-
tomy additionally removes a rich source of other vasoactive
substances [53, 971 and, as I already stated, fully one-half of
patients effectively treated with ACE inhibitors still develop
renal failure [77, 79]. Thus I accept the implication in your
question that other, as-yet-uncharacterized mechanisms are at
work, at least in some patients, and further, that the benefits of
using ACE inhibitors in part might be due to a class action of
these agents operating outside their targeted antihypertensive,
angiotensin-inhibiting role. The studies to which you refer in the
hypertensive rat with hypertrophic cardiomopathy underscore
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the role of angiotensin in promoting vascular growth indepen-
dent of its vasoconstrictor properties [104]. This angiogenic
effect of angiotensin also has been demonstrated in studies of
glomerular growth in maturing rat kidneys, where ACE inhibi-
tion retards growth [105]. Perhaps of additional relevance to
your question is the observation that captopril, given its D-pen-
icillamine-like sulfydryl group, does not produce any skin-
softening effects in patients with scieroderma [821.
DR. MICHAEL CARMODY (Consultant Nephrologist, Beau-
mont Hospital, Dublin): How early in the course of scieroderma
do patients manifest the abnormal immunologic markers, which
may represent a common pathogenetic pathway for many
connective tissue disorders?
DR. D0N0H0E: Your question touches on some fundamental
aspects of scleroderma. These abnormal antibodies are almost
certainly present very early, even before clinical illness be-
comes manifest [43, 44]. It is tempting to speculate that they are
not inherently toxic at the tissue level, but rather that they are
markers for intracellular, indeed, intranuclear perturbation and
might, for example, disrupt genetic encoding for normal fibro-
blast function [34, 38, 39]. By invoking this hypothesis, one can
take the pathogenesis of scleroderma all the way back to the
molecular genetic level. Perhaps in keeping with these remarks
is the observation that maneuvers that effectively reduce or
remove these abnormal antibodies are of doubtful benefit in
patients with established scleroderma [45—47, lOll.
DR. BRENDAN DUFFY (Consultant Nephrolo gist, University
Hospital, Gaiway, Ireland): You commented on tissue-culture
studies of fibroblasts from scieroderma-involved skin. Are such
studies useful in monitoring the clinical progress of the condi-
tion or in the study of putative therapies for scleroderma?
DR. D0N0H0E: In-vitro scleroderma fibroblast preparations
are robust and can go through several subculture phases while
continuing to produce excess collagen [34, 35]. You can shut
down this collagen synthesis by adding various agents (D-
penicillamine, mast cell stabilizers, or gamma-interferon) or
stimulate it by adding bleomycin [13, 36, 37, 391. One can
appreciate the significance of the cultured fibroblast in address-
ing parts of the pathogenetic process in scleroderma as well as
in the evaluation of multiple potential therapeutic agents. It is
probably not applicable to the clinical monitoring of an individ-
ual patient's course or response to systemic therapy, however.
DR. GiLLIAN MURPHY (Consultant Dermatologist, Mater!
Beaumont Hospitals, Dublin): Mast cells are present in greatly
increased numbers in the skin in the early phases of sclero-
derma [106]. Are excessive numbers of mast cells present in the
kidneys of these patients?
DR. D0N0H0E: I am aware of this abundance of mast cells in
the dermis. Claman, in particular, has focused considerable
attention on the mast cell as a potential effector cell in the
development of fibrosis [36, 106]. However, I am unaware of
any studies confirming a surfeit of mast cells in the kidney.
DR. JOSEPH WALSHE (Consultant Nephrolo gist, Beaumont
Hospital): As you pointed out, the development of overt renal
disease is a very poor prognostic sign for these patients.
However, not all patients develop this complication. Are there
any early warning signs that we could use as predictors of
incipient renal involvement?
DR. DON0H0E: The short answer to your question is no.
Once proteinuria and azotemia develop, it is clear that renal
disease already has arrived. I'm certain that the quest for subtle
harbingers of renal involvement ultimately will prove success-
ful, but so far it has been frustrating. As a general statement,
but perhaps not entirely a propos to your question, it can be
said that a number of unfavorable overall prognostic features
have been identified, including the following: the presence of
diffuse scieroderma versus CREST syndrome, absence of anti-
centromere antibodies, severely abnormal nailfold capillaros-
copy, rapid progression of dermal sclerosis, the absence of
Raynaud's phenomenon, the presence of circulating immune
complexes, and elevated plasma renin activity [32, 65, 661. That
these are only general guidelines is underscored by the obser-
vation that plasma renin activity can be normal in as short an
interval as one week before the onset of scleroderma renal crisis
[74]. I would be interested in seeing data on microalbuminuria
measurements in patients with scleroderma who have no overt
renal involvement.
DR. BILLY NELSON (Consultant Nephrolo gist, Belfast City
Hospital, Belfast, Northern Ireland): I was interested to learn
that your second patient remains hypertensive following her
successful kidney transplant. I have one patient with scleroder-
ma-induced renal failure being treated with maintenance hemo-
dialysis, and he tolerates excessive interdialytic weight gains
extremely badly, My question is a two-part one: Do you think
that hypertension in these patients is due to a "hidebound"
vascular tree? Are you monitoring your patient in any way that
differs from the way you monitor other patients who have
received renal transplants?
DR. DONOHOE: I'm quite sure that our patient has noncom-
pliant blood vessels, Whether this is actually due to fibrosis
creating a "hidebound" vasculature is difficult to decide, as
there is certainly a contribution from hypertension-related
atherosclerosis. During her time on hemodialysis, she showed
the classic hypertension-weight relationship common to most
dialysis patients. The advanced changes seen in the blood
vessels on renal biopsy, as well as her previous severe hyper-
tensive retinopathy, surely are indicative of widespread, sys-
temic arteriopathy. Our monitoring strategy is no different from
that used for other patients who have received transplants. I
recognize that she already demonstrates a number of potential
risk factors. She is hypertensive, her urine shows a trace of
protein, and arguably, she has mild impairment of renal func-
tion. I am concerned also about the suggested potential for
cyclosporine-induced stimulation of endothelin [55, 95]. How-
ever, I am glad to say that she currently is doing very well
overall, and we shall just have to wait and see. She is receiving
an ACE inhibitor!
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